English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The antifibrinolytic agent aprotinin, a naturally occurring serine protease inhibitor, was removed from the worldwide market in October 2007.[1][1] Aprotinin and two other antifibrinolytic agents (the lysine analogues tranexamic acid and aminocaproic acid) had been used in cardiac surgery to

Regulatory decisions pertaining to aprotinin may be putting patients at risk